Latest aTyr Pharma Stories
First Physiocrine-Based Therapeutic Administered to Patients SAN DIEGO, Jan.
- Industry Veteran Established Immunology Research Programs at NovoNordisk, ZymoGenetics SAN DIEGO and HONG KONG, Nov.
Architect of Novel Translational Rare Disease Programs at NIH Adds Depth to Existing Team of Rare Disease Experts SAN DIEGO and HONG KONG, Oct.
Publication in Science Unveils Novel, Diverse and Separate Biological Functions That Can Be Harnessed Therapeutically to Mediate a Wide Range of Human Disease SAN DIEGO and HONG KONG,
SAN DIEGO, July 14, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise announced today, the scientific publication of a splice variant of a tRNA synthetase
First Demonstration of Safety and Tolerability of Physiocrines SAN DIEGO, May 21, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise, announced today
Clinical Leader Brings Strong Drug Development Background and Expertise SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced
SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today the appointment of Ed Penhoet, Ph.D., to the Company's board
First Administration to Human Subjects of a New Protein Class, Physiocrines SAN DIEGO, Feb.
Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb.